Ardelyx, Inc. (ARDX): Revenue
$407.32M
Year ended 2025-12-31
$450.89M
Trailing 12 months to 2026-06-30
+98.4%
3-year compound annual growth
n/m
5-year compound annual growth
+32.7%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $407.32M | +22.1% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $333.62M | +168.1% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $124.46M | +138.6% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $52.16M | +416.6% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $10.10M | +33.4% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $7.57M | +43.4% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $5.28M | +102.6% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $2.61M | -93.8% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $42.00M | n/a | 2020-03-06, From 2017-01-01 |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | $24.03M | -24.0% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $31.62M | +9.3% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $28.93M | +434.7% | 2016-03-04, From 2013-01-01 |
| 2012-12-31 | $5.41M | n/a | 2015-03-05, From 2012-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $407.32M | +22.1% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $411.33M | +14.7% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $386.01M | +6.8% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $372.07M | +123.4% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $457.18M | +15.0% |
| MannKind Corp (MNKD) | 2025-12-31 | $348.97M | +22.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.73M | +110.5% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $502.08M | +126.3% |
Compare ARDX, INVA, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗